{"id":"placebo-double-blind","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL267632","moleculeType":"Small molecule","molecularWeight":"1259.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance administered in double-blind trials where neither the patient nor the investigator knows whether the subject is receiving active drug or placebo. Any clinical benefit observed in the placebo group is attributed to the placebo effect (psychological and contextual factors), allowing researchers to isolate the true pharmacological efficacy of the test drug by comparing outcomes between placebo and active treatment arms.","oneSentence":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials to measure the true efficacy of an investigational drug.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:47.874Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07496021","phase":"NA","title":"Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease","status":"RECRUITING","sponsor":"CKD Bio Corporation","startDate":"2026-02-23","conditions":"Early Alzheimers Disease","enrollment":60},{"nctId":"NCT06806592","phase":"PHASE3","title":"A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-09-13","conditions":"Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases","enrollment":400},{"nctId":"NCT07433556","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers","status":"RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2026-03-23","conditions":"Healhty","enrollment":86},{"nctId":"NCT06817356","phase":"PHASE2","title":"A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-02-06","conditions":"Alcohol Use Disorder","enrollment":300},{"nctId":"NCT07495202","phase":"PHASE1","title":"A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JunTop Biosciences Co., LTD","startDate":"2026-03-30","conditions":"Health Volunteer","enrollment":180},{"nctId":"NCT07037433","phase":"PHASE3","title":"Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-07-25","conditions":"Atherosclerotic Cardiovascular Disease, Overweight, Obesity","enrollment":12800},{"nctId":"NCT06030362","phase":"NA","title":"Probiotic Intervention Study","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-07-18","conditions":"Obesity, Food Addiction","enrollment":100},{"nctId":"NCT07494305","phase":"PHASE2","title":"Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.","status":"RECRUITING","sponsor":"LB Pharmaceuticals Inc.","startDate":"2026-01-23","conditions":"Bipolar I Disorder","enrollment":320},{"nctId":"NCT05754957","phase":"PHASE3","title":"A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-07","conditions":"Acute Coronary Syndrome","enrollment":14194},{"nctId":"NCT06450444","phase":"NA","title":"The RECLAIM Study.","status":"RECRUITING","sponsor":"Salvia BioElectronics","startDate":"2024-06-24","conditions":"Chronic Migraine, High Frequency Episodic Migraine","enrollment":110},{"nctId":"NCT07072468","phase":"PHASE2","title":"Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)","status":"RECRUITING","sponsor":"VM Therapeutics LLC","startDate":"2025-12-12","conditions":"Chemotherapy-induced Peripheral Neuropathy, Drug-Induced Nephropathy","enrollment":16},{"nctId":"NCT06456346","phase":"PHASE3","title":"Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-16","conditions":"Essential Thrombocythemia","enrollment":300},{"nctId":"NCT05718375","phase":"PHASE2","title":"Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria","status":"COMPLETED","sponsor":"Curacle Co., Ltd.","startDate":"2023-02-14","conditions":"Diabetic Nephropathies","enrollment":240},{"nctId":"NCT07431086","phase":"PHASE2","title":"Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-16","conditions":"Overweight or Obesity","enrollment":120},{"nctId":"NCT03574909","phase":"PHASE3","title":"IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes","status":"COMPLETED","sponsor":"Royal College of Surgeons, Ireland","startDate":"2018-09-01","conditions":"Pre-Gestational Diabetes","enrollment":137},{"nctId":"NCT07149649","phase":"PHASE2, PHASE3","title":"Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2026-07","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer","enrollment":230},{"nctId":"NCT07498309","phase":"PHASE3","title":"Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-09","conditions":"Vaso-Occlusive Crises, Sickle Cell Disease","enrollment":144},{"nctId":"NCT07495813","phase":"PHASE1","title":"A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Stable Coronary Artery Disease, Healthy Volunteers","enrollment":196},{"nctId":"NCT07046819","phase":"PHASE2","title":"Tirzepatide in MetALD","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2026-04-01","conditions":"Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder","enrollment":120},{"nctId":"NCT04544449","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-10-26","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":985},{"nctId":"NCT03375320","phase":"PHASE3","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-26","conditions":"Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm","enrollment":298},{"nctId":"NCT04199104","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-05","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":511},{"nctId":"NCT05077904","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2021-12-07","conditions":"Stereotypical Prolonged Seizures","enrollment":350},{"nctId":"NCT05499130","phase":"PHASE2","title":"A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2022-09-30","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":290},{"nctId":"NCT07235917","phase":"PHASE2","title":"A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-11","conditions":"Functional Hypothalamic Amenorrhea (FHA)","enrollment":34},{"nctId":"NCT07498712","phase":"NA","title":"Effect of L. Reuteri LM1063 on Sleep Health Improvement","status":"RECRUITING","sponsor":"Lactomason Co., Ltd.","startDate":"2025-07-14","conditions":"Sleep Quality, Sleep Wake Disorders","enrollment":80},{"nctId":"NCT06631287","phase":"PHASE3","title":"Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID","status":"RECRUITING","sponsor":"Wes Ely","startDate":"2024-10-21","conditions":"Long COVID, Sars-CoV-2 Infection, Coronavirus Infections","enrollment":550},{"nctId":"NCT06344104","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-08","conditions":"Uncontrolled Hypertension, Resistant Hypertension","enrollment":326},{"nctId":"NCT06564818","phase":"PHASE3","title":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","status":"RECRUITING","sponsor":"Cybin IRL Limited","startDate":"2024-12-17","conditions":"Major Depressive Disorder","enrollment":220},{"nctId":"NCT06412666","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).","status":"RECRUITING","sponsor":"Cytokinetics","startDate":"2024-05-29","conditions":"Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy","enrollment":55},{"nctId":"NCT07419828","phase":"PHASE3","title":"A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-03-13","conditions":"Chronic Kidney Disease","enrollment":1978},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT06196879","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)","status":"COMPLETED","sponsor":"Upstream Bio Inc.","startDate":"2024-02-27","conditions":"Severe Asthma","enrollment":479},{"nctId":"NCT07210723","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Kardigan, Inc.","startDate":"2026-02-13","conditions":"Symptomatic Genetic Dilated Cardiomyopathy","enrollment":332},{"nctId":"NCT06072183","phase":"PHASE3","title":"A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-11-08","conditions":"Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo","enrollment":1571},{"nctId":"NCT03969004","phase":"PHASE3","title":"Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-06-04","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":415},{"nctId":"NCT07497087","phase":"PHASE3","title":"A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-06-09","conditions":"Systemic Sclerosis","enrollment":448},{"nctId":"NCT07266831","phase":"PHASE2, PHASE3","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-18","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":570},{"nctId":"NCT06128629","phase":"PHASE3","title":"MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)","status":"RECRUITING","sponsor":"Intellia Therapeutics","startDate":"2023-12-13","conditions":"Transthyretin Amyloidosis (ATTR) With Cardiomyopathy","enrollment":1200},{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT06727552","phase":"PHASE2","title":"A Study of Barzolvolimab in Patients With Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2024-12-18","conditions":"Atopic Dermatitis","enrollment":131},{"nctId":"NCT06450366","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-08","conditions":"Hypercholesterolemia","enrollment":301},{"nctId":"NCT06858579","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)","status":"RECRUITING","sponsor":"Dianthus Therapeutics","startDate":"2025-02-10","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":480},{"nctId":"NCT07497646","phase":"NA","title":"Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2025-01-01","conditions":"Chronic Migraine Headache, Chronic Tension-type Headache","enrollment":290},{"nctId":"NCT06439082","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Sickle Cell Disease","enrollment":315},{"nctId":"NCT06963827","phase":"PHASE3","title":"A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-07-15","conditions":"Kidney Disease","enrollment":347},{"nctId":"NCT06714253","phase":"PHASE1, PHASE2","title":"Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1","status":"RECRUITING","sponsor":"RiboX Therapeutics Ltd.","startDate":"2025-03-05","conditions":"Radiation-Induced Xerostomia and Hyposalivation","enrollment":42},{"nctId":"NCT04123795","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2020-01-21","conditions":"Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis","enrollment":49},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT03844061","phase":"PHASE2","title":"Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-29","conditions":"Systemic Sclerosis","enrollment":30},{"nctId":"NCT07459166","phase":"PHASE2","title":"A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade","status":"NOT_YET_RECRUITING","sponsor":"Clear Scientific, Inc.","startDate":"2026-04","conditions":"Fentanyl Overdose, Fentanyl Poisoning","enrollment":16},{"nctId":"NCT06948097","phase":"PHASE1","title":"Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies","status":"NOT_YET_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2026-04-01","conditions":"Lung Transplantation","enrollment":30},{"nctId":"NCT05630781","phase":"NA","title":"Orexin s Role in the Neurobiology of Substance Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2023-02-15","conditions":"Nicotine Dependence","enrollment":140},{"nctId":"NCT04849728","phase":"PHASE3","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventiva Pharma","startDate":"2021-08-19","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":1000},{"nctId":"NCT07046494","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder","status":"RECRUITING","sponsor":"Rapport Therapeutics Inc.","startDate":"2025-07-25","conditions":"Bipolar 1 Disorder","enrollment":224},{"nctId":"NCT07495943","phase":"NA","title":"Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia","status":"NOT_YET_RECRUITING","sponsor":"Haydarpasa Numune Training and Research Hospital","startDate":"2026-05-04","conditions":"Fibromyalgia Syndrome, Fibromyalgia","enrollment":200},{"nctId":"NCT06009926","phase":"PHASE2","title":"Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-04","conditions":"Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Occupational Malignant Neoplasm","enrollment":72},{"nctId":"NCT05318976","phase":"PHASE2","title":"A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation","status":"COMPLETED","sponsor":"Inmune Bio, Inc.","startDate":"2022-02-28","conditions":"Alzheimer Disease, Dementia, Brain Diseases","enrollment":208},{"nctId":"NCT07287670","phase":"PHASE2","title":"EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)","status":"NOT_YET_RECRUITING","sponsor":"Mediar Therapeutics","startDate":"2026-02","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":85},{"nctId":"NCT07493057","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-04-27","conditions":"Obstructive Sleep Apnea (OSA)","enrollment":140},{"nctId":"NCT06624228","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-10-21","conditions":"Psoriatic Arthritis","enrollment":684},{"nctId":"NCT07363694","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-11","conditions":"Moderate to Severe Chronic Obstructive Pulmonary Disease","enrollment":1156},{"nctId":"NCT06241313","phase":"PHASE3","title":"Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-03-25","conditions":"Migraine","enrollment":1300},{"nctId":"NCT04781387","phase":"PHASE2","title":"Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"Crestone, Inc","startDate":"2021-01-05","conditions":"Clostridioides Difficile Infection","enrollment":43},{"nctId":"NCT07133633","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-09-26","conditions":"Radiographic Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT07495592","phase":"NA","title":"The Acute Effects of Onnit Alpha Brain on Cognition and Mood States","status":"NOT_YET_RECRUITING","sponsor":"Applied Science & Performance Institute","startDate":"2026-04-16","conditions":"Cognitive, Mood and Cognitive Performance, Sleep Deprivation","enrollment":34},{"nctId":"NCT07221292","phase":"PHASE3","title":"Pivotal Study of N-acetyl-L-leucine for CACNA1A","status":"NOT_YET_RECRUITING","sponsor":"IntraBio Inc","startDate":"2026-09-01","conditions":"CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2","enrollment":60},{"nctId":"NCT07497399","phase":"PHASE2","title":"Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04","conditions":"Multiple Sclerosis","enrollment":120},{"nctId":"NCT04777409","phase":"PHASE3","title":"A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-18","conditions":"Early Alzheimer´s Disease","enrollment":1840},{"nctId":"NCT04858334","phase":"PHASE2","title":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-22","conditions":"Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma","enrollment":152},{"nctId":"NCT05152173","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2021-11-29","conditions":"Plantar Fibromatosis","enrollment":176},{"nctId":"NCT05366855","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP","status":"TERMINATED","sponsor":"Vanda Pharmaceuticals","startDate":"2022-04-21","conditions":"Generalized Pustular Psoriasis","enrollment":42},{"nctId":"NCT07332091","phase":"PHASE2","title":"Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2026-01-22","conditions":"Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis","enrollment":84},{"nctId":"NCT05893069","phase":"PHASE4","title":"Oxandrolone Multiligament Knee","status":"SUSPENDED","sponsor":"George F. Hatch","startDate":"2023-07-01","conditions":"Ligament Tear Knee","enrollment":60},{"nctId":"NCT07469527","phase":"NA","title":"Effects of Feel Free® Classic Tonic on Stress and Pharmacokinetics in Healthy Adults","status":"RECRUITING","sponsor":"Botanic Tonics, LLC","startDate":"2026-03-07","conditions":"Anxiety, Physiological Stress, Stress","enrollment":165},{"nctId":"NCT07284901","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2026-01-12","conditions":"Obesity With Diabetes, Overweight With Diabetes","enrollment":1700},{"nctId":"NCT07160608","phase":"PHASE2","title":"Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-11-26","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":75},{"nctId":"NCT06616974","phase":"PHASE2","title":"A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)","status":"RECRUITING","sponsor":"Tectonic Therapeutic","startDate":"2024-09-04","conditions":"Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction","enrollment":180},{"nctId":"NCT07222332","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-05","conditions":"Diabetes Mellitus, Type 1","enrollment":300},{"nctId":"NCT07498426","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)","enrollment":300},{"nctId":"NCT06132256","phase":"PHASE2","title":"MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2023-12-11","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":145},{"nctId":"NCT06280235","phase":"PHASE2","title":"A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-27","conditions":"Depressive Disorder, Major","enrollment":243},{"nctId":"NCT00003140","phase":"PHASE3","title":"Letrozole After Tamoxifen in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1998-08-24","conditions":"Breast Cancer","enrollment":5187},{"nctId":"NCT05121051","phase":"PHASE2","title":"Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-09-21","conditions":"Cigarette Smoking-Related Carcinoma","enrollment":135},{"nctId":"NCT06742723","phase":"PHASE3","title":"A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-03","conditions":"Chronic Kidney Disease and Hypertension","enrollment":5000},{"nctId":"NCT06840496","phase":"PHASE3","title":"To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome","status":"RECRUITING","sponsor":"Biomed Industries, Inc.","startDate":"2026-09-30","conditions":"Rett Syndrome","enrollment":210},{"nctId":"NCT07353307","phase":"PHASE3","title":"A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia After Abdominal Surgery in China.","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2025-12-30","conditions":"Pain After Abdominal Surgery","enrollment":333},{"nctId":"NCT07496034","phase":"PHASE3","title":"Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine: A Double-Blind Randomized Controlled Trial","status":"RECRUITING","sponsor":"Tsai, Chueh-Yi, MD","startDate":"2025-07-01","conditions":"Episodic Migraine","enrollment":40},{"nctId":"NCT04864314","phase":"NA","title":"Assessment of TetraSOD® Efficacy to Improve Semen Parameters in Men With Idiopathic Infertility","status":"COMPLETED","sponsor":"Fitoplancton Marino, S.L.","startDate":"2021-05-12","conditions":"Infertility, Male","enrollment":80},{"nctId":"NCT06063486","phase":"PHASE2","title":"Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2024-03-01","conditions":"Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome","enrollment":30},{"nctId":"NCT04251533","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-08","conditions":"Triple Negative Breast Neoplasms","enrollment":137},{"nctId":"NCT06290141","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-08-21","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":160},{"nctId":"NCT07022119","phase":"PHASE1","title":"A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-06-12","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":32},{"nctId":"NCT07050316","phase":"PHASE1","title":"Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects","status":"COMPLETED","sponsor":"Ceres Brain Therapeutics","startDate":"2025-03-14","conditions":"Neurologic Diseases, General","enrollment":48},{"nctId":"NCT07335198","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-05","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":30},{"nctId":"NCT07489885","phase":"PHASE2","title":"A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2026-05","conditions":"Psoriasis","enrollment":75},{"nctId":"NCT07498634","phase":"PHASE3","title":"Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS","status":"COMPLETED","sponsor":"Zhejiang Kanova Biopharmaceutical Co., LTD","startDate":"2023-09-21","conditions":"Phase III","enrollment":323},{"nctId":"NCT07493031","phase":"PHASE1","title":"A PhaseⅠ Study of HW252001 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","startDate":"2026-03-31","conditions":"IPF","enrollment":98},{"nctId":"NCT07037420","phase":"PHASE2","title":"ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-10-28","conditions":"Acromegaly","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":143,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"Placebo (double-blind)","genericName":"Placebo (double-blind)","companyName":"University of Rochester","companyId":"university-of-rochester","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}